Your browser is out-of-date!

Update your browser to view this website correctly. Update my browser now



Larval cyathostominosis

It is important to find out the cause of an outbreak and implement measures to prevent reoccurrence

The aetiology and prevention of larval cyathostom­inosis (LC) is a hazy area to say the least. The use of larvicidal anthelmintics such as fenbendazole and moxidectin has been the mainstay of the prevention of this disease for decades, but reliance on this method alone is not sustainable. Benzimidazole resistance is now widespread across the UK, rendering it useless in many instances (Lester et al., 2013; Stratford et al., 2014). Reduced length of action for the macrocyclic lactone (ML) drugs has been widely reported in the UK over the last 10 years (Tzelos et al., 2017; Molena et al., 2018). This has been regarded by many as a precursor to the development of anthelmintic resistance (AHR). Indeed, alarmingly, the first concrete report of ivermectin and moxidectin resistant cyathostomins has just been published in the US (Nielsen et al., 2020). The horses harbouring these parasites were imported from Ireland and, given the high levels of equine movement globally, we should assume that ML resistant cyathostomins are likely to become widespread. The take home message is that in the long run we can expect more frequent outbreaks of LC in vulnerable populations, with inadequate tools to treat it.

In light of the above, clinicians (especially those working with youngstock) may be increasingly unsure as to the best way to manage the risk and treatment of LC. The aim of this article is to clarify what is known and provide updates on advances in this area.

Risk factors for larval cyathostominosis

LC occurs when large numbers of encysted larvae simul­taneously develop and exit the large intestinal mucosa. This “mass emergence” is more likely in horses with heavy mucosal burdens in the late winter/early spring; it is more common in young horses but can occur at any age (Giles et al., 1985; Mair, 1993; Reid et al., 1995; Walshe et al., 2020). Contributing factors are poor pasture management com­bined with lack of effective anthelmintic treatment to eliminate, or prevent build-up of, infection. Treatment with ivermectin in horses with heavy mucosal burdens is also linked to the onset of LC (Walshe et al., 2020); hence, this drug should be used with caution in animals with suspected high mucosal burdens. Outbreaks are often seen in neglect cases or poorly managed yards but, importantly, may increasingly occur due to AHR.

Clinical presentation

Clinical signs of LC vary in severity and include rapid weight loss, diarrhoea, ventral oedema, abdominal pain and signs of endotoxaemia (Mair, 1993, 1994; Murphy et al., 1997; Love et al., 1999; Bodek et al., 2010; Walshe et al., 2020). LC has also been reported to cause caecal compromise, and so should also be a differential diagnosis in colic cases (Mair et al., 2010). There should be a high index of suspicion for LC in young horses presenting with the above signs, especially when combined with a history of poor worm management and when more than one animal is affected. A positive faecal egg count (FEC) is often absent, as disease occurs before the larvae have developed to adults and the females have started producing eggs (Giles et al., 1985; Murphy et al., 1997; Walshe et al., 2020). Red larvae in faeces are the textbook image for diagnosis of LC, but again, these are not always seen. The incorporation of the novel redworm ELISA (Tzelos et al., 2020) into the diagnostic toolkit may help to improve confidence of diagnosis where there is doubt; for example, high levels of antibody would support a positive diagnosis (Walshe et al., 2020).


Once a diagnosis of LC is suspected, supportive treat­ment to address any fluid and protein loss, coupled with anti-inflammatory and anthelmintic treatment, should be commenced. Immunosuppressive doses of prednisolone (1mg/kg) are advised 24 to 48 hours before anthelmintic treatment, to be tapered down gradually according to clinical response (Nielsen and Reinemeyer, 2018; Walshe et al., 2020). Moxidectin (0.4mg/kg) or five-day fenbendazole (10mg/kg) are both recommended to treat LC as they have larvicidal activity. However, resistance to fenbendazole is now widespread (Lester et al., 2013; Stratford et al., 2014), so, unless you have recent faecal egg count reduction test (FECRT) data from the same yard proving efficacy, then its use is not advisable. There are also data showing that fenbendazole may induce a greater inflammatory response than moxidectin (Steinbach et al., 2006); therefore, it may also be clinically preferable to use moxidectin. In cases with persistent pyrexia, non-steroidal anti-inflammatories (NSAIDs) can also be administered (Walshe et al., 2020). Furthermore, systemic antibiotic use may be indicated in moderate to severely affected cases, due to bacterial translocation across severely damaged mucosa (Kelly and Fogarty, 1993; Bodecek et al., 2010; Walshe et al., 2020). A recent case series reported that severely affected animals had persistent pyrexia and signs of endotoxaemia despite anthelmintic, steroid and NSAID administration (Walshe et al., 2020). Broad spectrum antibiotics (enrofloxacin 7.5mg/ kg PO and metronidazole 25mg/kg PO) were used in these cases, and resulted in recovery.

Co-grazing animals which have the same risk factors, but are clinically well, should also be assessed for risk of disease, and treated with prednisolone and moxidectin accordingly. Unfortunately, FEC are not useful to identify at-risk horses, as they have frequently been reported as low/absent in LC cases (see above). Thus, the redworm ELISA may also be useful in this instance to further evalu­ate risk. If in doubt, however, it is better to treat.

Dealing with the underlying lack of control

Once cases have been treated, it is important to find out what has led to the outbreak and implement measures to prevent future outbreaks. Much of this process will be based on clinical history (eg was monitoring and treat­ment in place? Which drugs were used, and when? Were they given at adequate dosage? Are they effective against mucosal stages? Are pastures routinely poo-picked and rotated?). However, there may be increasing numbers of examples where apparently adequate control was in place – yet clinical cases have still occurred. In these instances, AHR should be strongly suspected and FECRTs are recom­mended on any remaining untreated animals on the yard (American Association of Equine Practitioners, 2019). On larger establishments, FECRT (including monitoring for early egg reappearance for MLs) should be used routinely to monitor drug efficacy. Further routine advice for future worm control will be covered below.

Advice for routine prevention

With regards to routine prevention of LC, much advice is unchanged over recent years (Figure 1). The aim is to break the cycle of transmission over spring, summer and autumn to prevent build-up of infective larvae on pasture and reduce infection intensity. This is followed by larvi­cidal treatment in early winter. Superimposed on this is an increasing emphasis on the use of FEC to inform targeted treatment of high-shedding individuals, and thus reduce selection for AHR. As anthelmintics can be bought without a prescription, uptake for targeted strategies using FECs is not as high as it could or should be. FECs and the ELISA are often of equal or greater cost than a wormer, so there is certainly no financial incentive to use them. Further­more, a recent behavioural survey revealed that the threat of AHR was not enough to encourage FEC use in owners; however, increased “self-perceived” knowledge regarding anthelmintics and FECs led to higher intended uptake (Rose Vineer et al., 2017). Therefore, knowledge transfer events to engage owners in the science may be the best way forward to increase uptake for practice-led worm control programmes.

FIGURE (1) Prevention of larval cyathostominosis aims to break the cycle of transmission over spring, summer and autumn to prevent build-up of infective larvae on pasture and reduce infection intensity. NB This figure does not cover prevention of Parascaris equorum or Anoplocephala perfoliata

As egg reappearance rates shorten, and cases of AHR increase, clinicians may find themselves in a catch-22 situ­ation – anthelmintic will need to be given more frequently to prevent disease yet, in turn, this selects more strongly for AHR. The solution isn’t rocket science; simply the best way to reduce transmission under these circumstances is good old regular poo picking and effective pasture man­agement. On many larger establishments, poo-picking is often deemed to be too time consuming and the existential threat of AHR is not enough incentive to employ additional staff to do this. Sadly, in time, their hand may be forced by outbreaks of LC which will be far more costly.


American Association of Equine Practitioners


Internal parasite control guidelines [online]

Bodecek, S., Jahn, P., Dobesova, O. and Vavrouchova, E.


Equine cyathostomosis: case reports. Veterinární Medicína, 55(No. 4), 187-193

Giles, C. J., Urquhart, K. A. And Longstaffe, J. A.


Larval cyathostomiasis (immature trichonema-induced enteropathy): a report of 15 clinical cases. Equine Veterinary Journal, 17, 196-201

Kelly, J. C. and Fogarty, U. M. G.


Outbreak of larval cyathostomiasis on a thoroughbred stud farm. Irish Veterinary Journal, 46, 133-136

Lester, H. E., Spanton, J., Stratford, C. H., Bartley, D. J., Morgan, E. R., Hodgkinson, J. E., Coumbe, K., Mair, T., Swan, B., Lemon, G., Cookson, R. and Matthews, J. B.


Anthelmintic efficacy against cyathostomins in horses in Southern England. Veterinary Parasitology, 197, 189-196

Love, S., Murphy, D. and Mellor, D.


Pathogenicity of cyathostome infection. Veterinary Parasitology, 85, 113-122

Mair, T. S.


Recurrent diarrhoea in aged ponies associated with larval cyathostomiasis. Equine Veterinary Journal, 25, 161-163

Mair, T. S.


Outbreak of larval cyathostomiasis among a group of yearling and two-year-old horses. Veterinary Record, 135, 598-600

Mair, T. S., Sutton, D. G. M. And Love, S.


Caecocaecal and caecocolic intussusceptions associated with larval cyathostomosis in four young horses. Equine Veterinary Journal, 32, 77-80

Molena, R. A., Peachey, L. E., Di Cesare, A., Traversa, D. and Cantacessi, C.


Cyathostomine egg reappearance period following ivermectin treatment in a cohort of UK Thoroughbreds. Parasites & Vectors, 11

Murphy, D., Keane, M. P., CHANDLER, K. J. and Goulding, R.


Cyathostome-associated disease in the horse: Investigation and management of four cases. Equine Veterinary Education, 9, 247-252

Nielsen, M.K. and Reinemeyer, C. R.


Handbook of equine parasite control. Wiley Blackwell, Hoboken

Nielsen, M. K., Banahan, M. and Kaplan, R. M.


Importation of macrocyclic lactone resistant cyathostomins on a US thoroughbred farm. International Journal for Parasitology: Drugs and Drug Resistance, 14

Reid, S. W. J., Mair, T. S., Hillyer, M. H. And Love, S.


Epidemiological risk factors associated with a diagnosis of clinical cyathostomiasis in the horse. Equine Veterinary Journal, 27, 127-130

Rendle, D., Austin, C., Bowen, M., Cameron, I., Furtado, T., Hodgkinson, J., McGorum, B. and Matthews, J.


Equine de-worming: a consensus on current best practice. UK-Vet Equine, 3, 114

Rose Vineer, H., Vande Velde, F., Bull, K., Claerebout, E. and Morgan, E. R.


Attitudes towards worm egg counts and targeted selective treatment against equine cyathostomins. Preventive Veterinary Medicine, 144, 66-74

Steinbach, T., Bauer, C., Sasse, H., Baumgärtner, W., Rey-Moreno, C., Hermosilla, C., Damriyasa, I. M. and Zahner, H.


Small strongyle infection: consequences of larvicidal treatment of horses with fenbendazole and moxidectin. Veterinary Parasitology, 139, 115-131

Stratford, C.H., Lester, H.E., Pickles, K.J., McGorum, B.C. and Matthews, J.B.


An investigation of anthelmintic efficacy against strongyles on equine yards in Scotland. Equine Veterinary Journal, 46, 17-24

Tzelos, T., Barbeito, J. S. G., Nielsen, M. K., Morgan, E. R., Hodgkinson, J. E. and Matthews, J. B.


Strongyle egg reappearance period after moxidectin treatment and its relationship with management factors in UK equine populations. Veterinary Parasitology, 237, 70-76

Tzelos, T., Geyer, K. K., Mitchell, M. C., McWilliam, H. E. G., Kharchenko, V. O., Burgess, S. T. G. and Matthews, J. B.


Characterisation of serum IgG(T) responses to potential diagnostic antigens for equine cyathostominosis. International Journal for Parasitology, 50, 289-298

Walshe, N., Mulcahy, G., Crispie, F., Cabrera‐Rubio, R., Cotter, P., Jahns, H. and Duggan, V.


Outbreak of acute larval cyathostominosis – A “perfect storm” of inflammation and dysbiosis. Equine Veterinary Journal

Laura Peachey

Laura Peachey, BVSc, BSc, PhD, is Lecturer in Veteri­nary Parasitology at Bristol Veterinary School. Laura trained as an equine vet, completing an internship in equine medicine and surgery at Liverpool vet school before moving into academia. Her research focuses on identifying mechanisms of anthelmintic resistance, and novel options for control, in cyathostomins.

More from this author

Looking for a range of resources, insights and CPD all in one place?

Join the ALL-NEW Veterinary Practice community; the online platform with nugget-sized, CPD-accredited veterinary training and resources!

Everything you need for your professional development, delivered by experts.

One place. One login. It’s online. All the time.

Annual subscription: £299 for Vets and £199 for Vet Nurses

Subscribe Now